The capsule was developed by the pharmaceutical company Lupin and is a generic equivalent to Boehringer Ingelheim’s Spiriva HandiHaler.
Lupin has launched its generic tiotropium bromide inhalation powder capsule for the treatment of chronic obstructive pulmonary disease (COPD) in the US, the pharmaceutical company announced in a press release.1
The tiotropium bromide inhalation powder from Lupin is a once daily inhaler that delivers 18 mcg of tiotropium bromide to help control the symptoms of COPD. The medication is designed to relax airways in the lungs to help keep them open for 24 hours. It is a generic equivalent to the Spiriva HandiHaler from Boehringer Ingelheim.
“We are delighted to announce the launch of generic Spiriva HandiHaler in the US, the first generic to this important drug for COPD,” Vinita Gupta, CEO of Lupin, said in a release.1 "This launch is a testament to our commitment to advancing healthcare accessibility and is a result of years of hard work and dedication to building our complex products and respiratory franchise.”
Lupin says that it hopes the launch of its generic tiotropium bromide inhalation powder capsule will help alleviate the burden of COPD for patients across the nation. COPD now impacts over 15 million adults in the US and is ranked as the country’s fourth leading cause of death.
The FDA approved Lupin’s Abbreviated New Drug Application for tiotropium bromide inhalation powder capsule in June. The product is manufactured at the pharmaceutical company’s facility in India. Lupin said the Spiriva HandiHaler had estimated annual sales of $1,264 million in the US in 2023.
"Being the first to bring an FDA-approved generic version of Spiriva in the US further reaffirms our commitment to enhancing the well-being of COPD patients for a healthier future,” said Gupta.